0001209191-21-009047.txt : 20210209
0001209191-21-009047.hdr.sgml : 20210209
20210209195600
ACCESSION NUMBER: 0001209191-21-009047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210205
FILED AS OF DATE: 20210209
DATE AS OF CHANGE: 20210209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Poukalov Konstantin
CENTRAL INDEX KEY: 0001678736
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39971
FILM NUMBER: 21608653
MAIL ADDRESS:
STREET 1: C/O KADMON HOLDINGS, LLC
STREET 2: 450 E 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Landos Biopharma, Inc.
CENTRAL INDEX KEY: 0001785345
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 815085535
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 KRAFT DRIVE, SUITE 216
CITY: BLACKSBURG
STATE: VA
ZIP: 24060
BUSINESS PHONE: 540-818-2844
MAIL ADDRESS:
STREET 1: 1800 KRAFT DRIVE, SUITE 216
CITY: BLACKSBURG
STATE: VA
ZIP: 24060
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-05
0
0001785345
Landos Biopharma, Inc.
LABP
0001678736
Poukalov Konstantin
C/O LANDOS BIOPHARMA, INC.
1800 KRAFT DRIVE, SUITE 216
BLACKSBURG
VA
24060
1
0
1
0
Common Stock
2021-02-05
4
P
0
27453
11.14
A
14647181
I
By funds
Common Stock
2021-02-08
4
P
0
34611
11.38
A
14681792
I
By funds
Common Stock
2021-02-08
4
P
0
86671
12.53
A
14768463
I
By funds
Common Stock
2021-02-08
4
P
0
1771
13.10
A
14770234
I
By funds
Common Stock
2021-02-09
4
P
0
64730
13.80
A
14834964
I
By funds
Common Stock
2021-02-09
4
P
0
34951
14.60
A
14869915
I
By funds
The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.
These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive.
Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive.
These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive.
These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive.
These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive.
These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive.
/s/ Eric W. Blanchard, Attorney-in-Fact
2021-02-09